Select Page

Price action beats all: it’s my credo when it comes to investing. At the end of the day, people can talk all they want, but it’s the performance that counts – and the doubters are usually just jealous that they didn’t find the hidden treasures like this one amazing cannabis stock.

But they didn’t bother to do the research, speak to key industry experts, and crunch the numbers like we did. In hindsight, it should be no surprise that Pure Global Cannabis Inc. (TSX-V: PURE, OTC: PRCNF) has been such a rainmaker for our loyal readers and viewers who followed our alerts and took early positions.

Again, it’s the due diligence that made all the difference: Pure Global CEO Malay Panchal had been working on securing a Canadian sales license that would naturally give a huge competitive advantage to any emerging cannabis company. As a result, we sent out the alert and recommended that patient investors sit tight with their PURE/PRCNF shares.

Shortly afterwards, the news hit the headlines and there was no stopping Pure Global from powering its way to the top:


Words like “jumps” and “moved sharply higher” are no exaggeration, as PURE shares leaped 51% that day from just CAD$0.195 all the way to an incredible CAD$0.30. It was a sight to behold, and we’re still getting messages about it from appreciative readers of our newsletter.

93% Of Investors Generate Annual Returns, Which Barely Beat Inflation.

Wealth Education and Investment Principles Are Hidden From Public Database On Purpose!

Build The Knowledge Base To Set Yourself Up For A Wealthy Retirement and Leverage The Relationships We Are Forming With Proven Small-Cap Management Teams To Hit Grand-Slams!

All told, Pure Global Cannabis stock shares gained 100% since we started covering it at CAD$0.12 in December, but there’s plenty of room for company growth and stock price appreciation, as PURE was severely underpriced and is still a terrific value compared to other players in the international cannabis space.

Pure Global is now able to expand its operations dramatically, as the company anticipates growing to 70 SKUs (stock-keeping units) by mid-2019, including adding extracted oil products and vape pens. Furthermore, the new sales license means that eligible, pre-registered Canadian medical cannabis patients can soon choose from 24 premium cannabis products offered by Puresinse through their Website,


Moreover, as part of Puresinse’s continued commitment to the medical community, the company is leading one of the largest real-world evidence-based clinical studies in conjunction with the Appletree Medical Group and one of the largest clinical research organizations in the world.

The clinical data will provide necessary data points for guidance in the therapeutic benefits of specific cannabis strains for commonly reported medical symptoms. This evidence will guide Puresinse’s future pharmaceutical product and consumer product development plans and provide the medical community with peer-reviewed data on the efficacy of medical cannabis for a range of conditions.

So really, the granting of the sales license is only the beginning. We’re 100% bullish on our position in Pure Global Cannabis and we expect to receive many more “thank you” messages from investors as the stock prices continue to reach new all-time highs.

Best Regards,

Thomas Hugh

Governments Have Amassed ungodly Debt Piles and Have Promised Retirees Unreasonable Amounts of Entitlements, Not In Line with Income Tax Collections. The House of Cards Is Set To Be Worse than 2008! Rising Interest Rates Can Topple The Fiat Monetary Structure, Leaving Investors with Less Than Half of Their Equity Intact!

Protect Yourself Now, By Building A Fully-Hedged Financial Fortress!

Legal Notice: This work is based on SEC filings, current events, interviews, corporate press releases and what we’ve learned as financial journalists. It may contain errors and you shouldn’t make any investment decision based solely on what you read here. It’s your money and your responsibility. Never base any decision off of our emails. Never base any decision off of our emails. stock profiles are intended to be stock ideas, NOT recommendations. The ideas we present are high risk and you can lose your entire investment, we are not stock pickers, market timers, investment advisers, and you should not base any investment decision off our website, emails, videos, or anything we publish. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this profile was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. Never base any investment decision from information contained in our website or emails or any or our publications. Our report is not intended to be, nor should it be construed as an offer to buy or sell, or a solicitation of an offer to buy or sell securities, or as a recommendation to purchase anything. We have entered into a three year agreement with the company, purchased shares, and have received three hundred and ninety thousand dollars paid for directly by the company for digital marketing. This publication may provide the addresses or contain hyperlinks to websites; we disclaim any responsibility for the content of any such other websites. Please use our site as a place to get ideas. Enjoy our videos and news analysis, but never make an investment decision off of anything we say. The information herein is not intended to be personal legal or investment advice and may not be appropriate or applicable for all readers. If personal advice is needed, the services of a qualified legal, investment or tax professional should be sought.

Please read our full disclaimer at